TG Therapeutics (TGTX) Misses Q2 EPS by 10c

TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of ($0.34), $0.10 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $16.3 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Tutor Perini launches $400M senior notes offering due 2033
• Micron Technology (MU) PT Raised to $1,550 at Needham